特发性肺纤维化患者的相对环境与社会劣势
研究基于加州大学旧金山分校纵向数据库603例IPF患者,将住址地理编码后链接CalEnviroScreen 3.0量化环境负担。结果显示,CES评分越高与基线FVC和DLCO越低相关,最高人群脆弱性四分位组抗纤维化治疗使用率更低。
要点
- 较高环境劣势与IPF患者基线FVC和DLCO较低相关。
- 人群脆弱性最高四分位组抗纤维化治疗使用率低于最低组。
- 环境与社会劣势对IPF患者具有实际影响。
核心结论
- 较高环境暴露与脆弱性同IPF患者较低基线肺功能及较低抗纤维化药物使用相关。
研究设计与样本
- 从加州大学旧金山分校纵向数据库识别IPF患者,住址地理编码后链接CalEnviroScreen 3.0,共纳入603例患者。
主要发现
- 较高CES评分与较低基线FVC相关(β=-0.073,95%CI -0.13至-0.02;p=0.006)。
- 较高CES评分与较低基线DLCO相关(β=-0.11,95%CI -0.16至-0.06;p<0.001)。
- 最高人群脆弱性四分位组患者入组时使用抗纤维化治疗的可能性低于最低四分位组(OR=0.33;95%CI 0.18至0.60;p=0.001)。
- CES与死亡率的关联被提示,但敏感性分析结果不一致。
- 研究队列的相对劣势似乎低于一般人群。
临床怎么用
- 评估IPF患者时,可关注其环境与社会劣势,因其与较差的基线肺功能和较低的抗纤维化治疗使用相关。
局限性
- CES与死亡率的关联在敏感性分析中结果不一致。
- 研究队列的相对劣势似乎低于一般人群,可能影响外推性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Air pollution exposure is associated with disease severity, progression and mortality in patients with idiopathic pulmonary fibrosis (IPF). Combined impacts of environmental and socioeconomic factors on outcomes in patients with IPF are unknown. The objectives of this study were to characterise the relationships between relative environmental and social disadvantage with clinical outcomes in patients with IPF. METHODS: Patients with IPF were identified from a longitudinal database at University of California, San Francisco. Residential addresses were geocoded and linked to the CalEnviroScreen 3.0 (CES), a tool that quantifies environmental burden in California communities, combining population, environmental and pollution vulnerability into individual and composite scores (higher scores indicating greater disadvantage). Unadjusted and adjusted linear and logistic regression and Fine and Gray proportional hazards models were used. RESULTS: 603 patients were included. Higher CES was associated with lower baseline forced vital capacity ( β =-0.073, 95% CI -0.13 to -0.02; p=0.006) and diffusion capacity of the lung for carbon monoxide ( β =-0.11, 95% CI -0.16 to -0.06; p<0.001). Patients in the highest population vulnerability quartile were less likely to be on antifibrotic therapy (OR=0.33; 95% CI 0.18 to 0.60; p=0.001) at time of enrolment, compared with those in the lowest quartile. An association between CES and mortality was suggested, but sensitivity analyses demonstrated inconsistent results. Relative disadvantage of the study cohort appeared lower compared with the general population. CONCLUSIONS: Higher environmental exposures and vulnerability were associated with lower baseline lung function and lower antifibrotic use, suggesting that relative socioenvironmental disadvantage has meaningful impacts on patients with IPF.
引用
- Avitzur N, Noth EM, Lamidi M, et al. Relative environmental and social disadvantage in patients with idiopathic pulmonary fibrosis. Thorax. 2021. PMID: 34949724. doi:10.1136/thoraxjnl-2021-217652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。